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Abstract
Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide
3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to develop novel treatments for
cancers that are not eligible for the currently approved targeted therapies. To this end, we generated specific
antibodies (Abs) against domain 1 (D1) and domain 3 (D3) of HER3 that recognize epitopes that do not overlap
with the neuregulin-binding site. The fully human H4B-121 Ab and the mouse monoclonal Abs 16D3-C1 and 9F7-
F11 inhibited tumor growth in nude mice xenografted with epidermoid, pancreatic, or triple-negative breast cancer
cells. The combination of one anti-HER3 Ab and trastuzumab improved tumor growth inhibition in mice xenografted
with HER2low cancer cell lines, for which trastuzumab alone shows no or moderate efficiency. Ab-induced disruption
of tumor growth was associated with G1 cell cycle arrest, proliferation inhibition, and apoptosis of cancer cells.
Anti-HER3 Abs blocked HER2/HER3 heterodimerization and HER3 phosphorylation at the cell membrane, leading
to inhibition of phosphorylation of the downstream AKT targets murine double minute 2, X-linked inhibitor of
apoptosis, and forkhead box O1. This study demonstrates that anti–HER3 D1 and D3 Abs could represent a
new option for immunotherapy of pancreatic and triple-negative breast cancers.
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Introduction
Cell plasticity is one of the main cancer features and leads to the rapid
therapeutic escape of tumor cells following the initial response. The
human epidermal growth factor receptor (HER) family includes four
distinct receptors [epidermal growth factor receptor (EGFR; HER1 or
ErbB1), HER2, HER3, and HER4] and 11 ligands [e.g., EGF and
neuregulins (NRGs)] and is one of the most extensively studied plas-
ticity network [1]. The HER3 receptor retains low level of kinase
activity, sufficient to trans-autophosphorylate its intracellular region
[2]. After binding to NRG, HER3 is mainly activated through hetero-
dimerization with other tyrosine kinase receptors, and the level of
expression and composition of such heterodimers play a role in the
diversification of downstream signaling and oncogenic effects. Such
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plasticity depends on the level of stimulation, nature of the ligand, cell
type, and receptor density and can be affected by exposure to anti-
bodies (Abs) [3] that might thus contribute to HER3 regulation
[4]. A specific feature of HER3 signaling activity is its unique ability
to directly activate the PI3K/AKT axis, which is at the crossroad of
many downstream pathways that involve the apoptosis-related pro-
teins murine double minute 2 (MDM2), forkhead box O1 (FoxO1),
and X-linked inhibitor of apoptosis (XIAP), the proliferation-related
proteins cyclin-dependent kinase inhibitor 1B and glycogen synthase
kinase 3 (GSK3), and the ribosomal protein S6 [5]. Consequently,
the PI3K/AKT pathway controls different biologic processes, such
as cell growth, survival and apoptosis, nutrient sensing, and metabolic
regulation and is implicated in tumor initiation and progression. Indeed,
HER3 genetic ablation impairs in vivo PI3K/AKT-dependent mam-
mary tumorigenesis [6].
HER3 expression correlates with tumor progression and reduced
survival of patients with pancreatic [7], breast [8], and ovarian cancers
[9], malignant melanoma and metastases [10], gastric carcinoma [11],
and head and neck squamous cell carcinoma [12]. HER3 overexpres-
sion is significantly associated with poor prognosis [13] and worse
metastasis-free survival [14] in colorectal carcinomas. Importantly,
in breast cancer, patients with HER2 non-amplified tumors are not
eligible for trastuzumab treatment and often these tumors are “pro-
grammed” to express HER3 [8]. Similarly, pancreatic cancers, which
are not eligible for targeted therapies, also show programmed HER3
overexpression [7]. Moreover, HER2-amplified breast tumors, which
become resistant to trastuzumab after prolonged treatment, are “re-
programmed” to strongly express HER3 [15] Cetuximab resistance
is also associated with HER3 overexpression in lung [16], colorectal
[17], and pancreatic [18] cancers, together with deregulation of EGFR
internalization/degradation [16,18]. Overexpression of HER3 and
activation of the PI3K/AKT pathway are also implicated in the devel-
opment of resistance to treatment with tyrosine kinase [19,20] and
PI3K [21] inhibitors, insulin-like growth factor 1 receptor (IGF1R)-
specific Abs [22], chemotherapeutic agents, and endocrine therapies.
Therefore, HER3 could be involved in the efficacy reduction of
many approved cancer monotherapies over time by 1) leading to
oversensitivity to HER3 ligands, such as NRGs [17], 2) switching
heterodimerization partner within the HER family or with other
kinase receptors [16,19], and 3) compensatory up-regulation of sig-
naling pathways [23]. Indeed, the current view is that EGFR-,
HER2-, or PI3K/AKT-targeted therapies (and probably other kinase
receptor–triggered pathways) will not be effective in the long term
unless combined with HER3 antagonists [21]. Most HER3-specific
Abs described to date act by blocking the NRG-binding site [13,24–
29]. However, as HER3 plays a key role in both ligand-independent
and ligand-dependent oncogenic signaling [5] through paracrine or
autocrine loops [30], we postulated that anti-HER3 Abs that are
not restricted to the ligand-binding site might have a wider scope
of action and could be associated with Abs that target the NRG-
binding site for a wider spectrum of action. The therapeutic efficacy
of the anti-EGFR Ab matuzumab [31], which does not target the
EGF-binding site, indicates that Abs that are not directed against
ligand-binding sites can have very interesting therapeutic perspectives
in oncology. We thus generated Abs that bind to motifs located on
domain 1 (D1), domain 3 (D3), and domain 4 (D4) of HER3 and
that, for some of them, do not overlap with the NRG-binding site.
These Abs reduced tumor growth in mice xenografted with different
cancer cell lines, independently of their NRG addiction or triple-
negative status. These Abs reduced HER2/HER3 heterodimerization
at the cell membrane of tumor cells and inhibited AKT-induced
phosphorylation of MDM2, FoxO1, XIAP, S6, and GSK3, leading
to reduced survival of tumor cells.
Materials and Methods
Reagents
Trastuzumab was obtained from Roche Pharma AG (Grenzach-
Wyhlen, Germany). The anti-HER2 Ab FRP5 was kindly provided
by Nancy Hynes (Basel, Switzerland). For Western blot analysis,
anti-HER2, anti-HER3, anti–phospho-HER3 (Tyr1289), anti-AKT,
anti–phospho-Ser473 and anti–Thr308 AKT, anti–phospho-MDM2, anti-
FoxO1, anti-S6, and anti–GSK3 α/β Abs were purchased from Cell
Signaling Technology (Beverly,MA). The anti–glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) Ab was purchased from Millipore (Billerica,
MA). The anti–phospho-HER2 (Tyr1196) and anti–HER3 (Tyr1262)
Abs, mouse and human HER3 (extracellular)–Fc recombinant pro-
teins, the Fc recombinant fragment, and the human recombinant
NRG extracellular domain (ECD) were fromRD Systems (Minneapolis,
MN). The anti–phospho-XIAP and anti–cyclin-dependent kinase
inhibitor 1B Abs were from Abcam (Cambridge, United Kingdom)
and Epitomics (Burlingame, CA), respectively. The irrelevant Px Ab,
used for control experiments, is an IgG1 monoclonal Ab that was
purified from the mouse myeloma cell line P3X63Ag8. Recombinant
human HER3 was acquired from Sino Biologicals (Beijing, China).
Cell Lines
The human pancreatic (BxPC-3), breast (MDA-MB-468), epider-
moid (A431), and lung (A549) cancer cell lines were from ATCC
(Rockville, MD). The mouse embryonic fibroblast NIH/3T3 cell line
was kindly provided by S. Schmidt (CNRS-UMR 5237, Montpellier,
France). EGFR-, HER2-, HER3-, HER2/HER3-, and EGFR/HER4-
transfected NIH/3T3 cell lines were obtained as previously described
[32]. Cell culture was detailed in the Supplementary Materials.
Ab Generation
Anti-HER3 human Ab (huAb) fragments were selected from the
human scFv phage libraryMG-Umab [33] and expressed as fully human
IgG1 for further characterization. HER3-specific mouse monoclonal
Abs were obtained by lymphocyte hybridization. Experiments were
detailed in the Supplementary Materials.
Xenograft Studies
All in vivo experiments were performed in compliance with the
national regulations and ethical guidelines for experimental animal
studies in an accredited establishment (Agreement No. C34-172-27).
Six-week-old female athymic mice, purchased from Harlan (Indiana-
polis, IN), were injected subcutaneously into the right flank with
A431 (0.7 × 106), A549 (10 × 106), BxPC3 (3.5 × 106), or MDA-
MB-468 (3 × 106) cells. Tumor-bearing mice were randomized in
the different treatment groups when tumors reached a minimum
size of 120 mm3 and were intraperitoneally treated with anti-HER3
Abs (15 mg/kg) or a combination of anti-HER3 Abs and trastuzumab
(ratio 1:1; 10 mg/kg of each Ab), every 2 days for 4 or 6 weeks. Tumor
dimensions were measured once or twice weekly and volumes were
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calculated with the formula: D1 × D2 × D3/2. Kaplan-Meier survival
estimates were calculated from the date of the xenograft until the date
of the event of interest and compared using the log-rank test. The
event of interest was reaching a tumor volume of 2000 mm3, when
mice were sacrificed.
HER3 Binding Studies
The binding specificity of selected Abs to soluble and membrane
HER3 was assessed by ELISA, flow cytometry, and surface plasmon
resonance and detailed in the Supplementary Materials.
Epitope Determination by SPOT Peptide Analysis
Two hundred thirteen overlapping pentadecapeptides that were
frame-shifted by one or three residues and that covered the amino
acid sequence of the HER3 ECD (amino acids 1–645) were synthe-
sized on cellulose membrane. After three washes in TBS buffer (50 mM
Tris, 137 mM NaCl, 2.68 mM KCl), membranes were saturated in
TBS containing 5% sucrose and casein-based blocking buffer (1:50;
Sigma-Aldrich, St Louis, MO) at 25°C overnight. After three washes
in TBS containing 0.05% Tween 20, cellulose-bound peptides were
probed with 1 to 10 μg/ml anti-HER3 Abs in TBS containing 5%
sucrose and casein-based blocking buffer and concomitantly or sequen-
tially incubated with peroxidase-conjugated goat F(ab)′2 secondary Ab
( Jackson ImmunoResearch, West Grove, PA) as appropriate, at 37°C
for 1.5 hours. After three washes in TBS containing 0.05% Tween 20,
Ab binding was detected with the ECLWestern Blotting Detection Kit
(PerkinElmer, Waltham, MA).
For SPOT alanine scanning analysis, 39 pentadecapeptides cor-
responding to the Ab-immunoreactive amino acid sequences previously
identified and the 15 alanine analogs of each peptide were synthesized
by the SPOT method. Ab reactivity of cellulose-bound peptides was
assayed as described above. Spot reactivity was evaluated by scanning
the membranes and measuring the spot intensities with ImageJ 1.44
(http://rsbweb.nih.gov/ij). SPOT critical residues (SCR), within the
HER3 epitopes recognized by the selected Abs, were identified on
the basis of the Ab-binding capacity of the relevant alanine analog
(at least 20% lower than that of the unmodified peptide sequence).
Flow Cytometry–Based NRG-Binding
Competition Experiments
Competition experiments were performed to quantify the ability of
NRG to inhibit Ab binding to HER3 in an SKBR3 cell–based assay.
To this end, 105 SKBR3 cells were pre-incubated with various con-
centrations of the competing NRG ligand on ice for 1.5 hours. After
one wash with phosphate-buffered saline (PBS)–1% BSA, anti–
HER3 Abs were added to each well at the concentration that gives
50% of the maximal binding, on ice for 1 hour. In some experiments,
NRG ligand and anti-HER3 Abs were co-incubated on ice for 2 hours
and showed similar results. Cells were then washed and incubated
with the appropriate fluorescein isothiocyanate (FITC)–conjugated
secondary Ab (1:60 dilution; Sigma) on ice for 45 minutes, before cyto-
metric analysis on a Quanta apparatus (Beckman Coulter, Fullerton, CA).
Cell Cycle, Proliferation, and Apoptosis Assays
The effect of HER3-specific Abs on the cell cycle was evaluated using
propidium iodide staining. Briefly, 300,000 BxPC3 tumor cells/well
were cultured in six-well microtiter plates for 24 hours and then serum
starved and synchronized in Roswell Park Memorial Institute medium
(RPMI) without fetal calf serum (FCS) for another 24 hours, before
co-incubation with 100 μg/ml anti-HER3 Abs and 100 ng/ml NRG.
Permeabilized cells were stained 24 hours later with propidium iodide
before flow cytometric analysis. For proliferation and apoptosis
assays, 50,000 BxPC3 cells/well were plated 1 day before starvation
(in RPMI–1% FCS). HER3-specific Abs and NRG were then added
for 120 hours. Cell proliferation was measured by incorporating
Alexa Fluor 488–conjugated 5-ethynyl-2′-deoxyuridine (Invitrogen,
Carlsbad, CA) during the last 30 hours of culture. Cell apoptosis
was assessed by incubation with fluorescence-conjugated Annexin V
and 7-aminoactinomycin D (Beckman Coulter). All experiments were
performed in triplicate.
Western Blot Analysis
Cellular fractionation of treated BxPC3 tumor cells and further
Western blot using appropriate Abs were detailed in the Supplemen-
tary Materials.
Homogeneous Time-resolved Fluorescence (HTRF) Analysis of
HER2/HER3 Heterodimerization
HER2/HER3 heterodimers were quantified using Ab-based time-
resolved fluorescence resonance energy transfer (TR-FRET) assay, as
previously described [32] and detailed in the Supplementary Materials.
Statistical Analysis
A linear mixed regression model was used to determine the rela-
tionship between tumor growth and the number of days post-graft.
The fixed part of the model included variables corresponding to the
number of days post-graft and the different groups. Interaction terms
were built into the model. Random intercept and random slope were
included to take into account the time effect. The coefficients of the
model were estimated by maximum likelihood and considered sig-
nificant at the 0.05 level. Survival rates were estimated from the date
of the xenograft until the date when the tumor reached a volume of
2000 mm3 using the Kaplan-Meier method. Median survival was
presented with 95% confidence intervals. Survival curves were com-
pared using the log-rank test. Statistical analyses were carried out
using the STATA 11.0 software (StataCorp, College Station, TX).
Results
Selected Anti-HER3 Abs Bind to the Extracellular Region of
Human HER3 but Not to the Other HER Receptors
Of the approximately 1000 mouse hybridomas screened, 10 mouse
Abs (moAbs) recognized the ECD of human HER3 but not mouse
HER3 (Figure 1A ) or the other HER family members (Figure 1B ) in
ELISA or flow cytometry assays. Among the 144 individual phage-
infected colonies selected from the human scFv library MG-Umab
[33], nine huAbs, expressed as fully human IgG1, specifically bound
to human HER3 (Figure 1A ) but not to other human HER receptors
(Figure 1B) and six cross-reacted with mouse HER3 (Figure 1A). The
selected huAbs and moAbs targeted soluble human HER3 (Figure 1A)
and membrane-anchored HER3 in NIH/3T3 cells that express HER3
alone or together with HER2 (HER2/HER3) (Figure 1B ). Surface
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plasmon resonance (Figure 1C ) showed that the huAbs H3A-122 and
H4B-121 and the moAbs 9F7-F11, 12H8-B11, and 16D3-C1 had the
best affinities (nanomolar range). The association rate (ka) for these Abs
ranged between 5 × 104 and 1 × 105 M−1 s−1, whereas their dissociation
rate (kd) was between 1 × 10
−3 and 1 × 10−4 s−1. Competition experi-
ments by flow cytometry demonstrated that moAb 9F7-F11 and huAb
H4B-25 did not compete with NRG, thus suggesting that these Abs do
not bind to the NRG-binding site (Figure 1D). Incubation of SKBR3
cells with 10−11 to 10−6 M NRG led to a ligand-dependent increase of
9F7-F11 binding to HER3. In contrast, the moAbs 12H8-B11 and
Figure 1. Selected anti-HER3 Abs bind to the extracellular region of human HER3 but not to the other HER receptors, with or without
interference with NRG binding. (A) Cross-reactivity of anti-HER3 moAbs and huAbs toward mouse or human soluble HER3 was
assessed by ELISAs. The absorbance values at 490 nm of the irrelevant control Abs Px and H3A-02 are indicated. Each value represents
the mean ± SD of triplicate determinations in three independent experiments. (B) Flow cytometric analysis of the anti-HER3 Ab binding
to NIH/3T3 fibroblasts transfected with membrane EGFR, HER2, HER3, HER2/HER3, or EGFR/HER4 in comparison to parental NIH/3T3
cells. Binding of the FITC-conjugated secondary Abs and of the control Abs H3A-02 and Px is also indicated. Results (geometric mean)
are representative of two different experiments. (C) BiaCore determination of the binding kinetics between anti-HER3 huAbs and recom-
binant human HER3 (3.12–6.25 nM) and between moAbs and human HER3 (extracellular)–Fc recombinant protein (77 nM), respectively.
(D) NRG interference with anti-HER3 Ab binding in HER3-positive SKBR3 cells was determined by competitive flow cytometry. The
binding (%) of the moAbs 9F7-F11 (□), 16D3-C1 (○), and 12H8-B11 (⋄), and of the huAbs H4B-121 (▴), H3A-122 (▪), and H4B-25 (♦)
to SKBR3 cells, after incubation with various NRG concentrations, is indicated. Each value represents the mean ± SD of triplicate
determinations in three independent experiments. No cell binding was observed when only the FITC-conjugated secondary Ab was
added after incubation with NRG.
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16D3-C1 as well as the huAbs H3A-122 and H4B-121 showed an
NRG-dependent decrease in binding to HER3, indicating that the epi-
topes recognized by these Abs are close to the NRG-binding site
(Figure 1D ). The NRG concentration that inhibited 50% binding
ranged between 2.5 and 4 nM.
Anti-HER3 Abs Target Epitopes that Are Located in
Domain 1, 3, or 4 of HER3
To identify the motifs recognized by the selected anti-HER3 Abs,
we used the SPOT method to synthesize 213 cellulose membrane-
bound pentadecapeptides that cover the entire ECD of human
HER3. Epitopes in D3 were recognized by the huAbs H4B-121
(amino acids 342–358; Figure 2A ) and H4B-25 (residues 460–
477), and H3A-122 bound to an epitope in D4 (amino acids
495–510). In contrast, the moAbs 9F7-F11 and 16D3-C1 showed
reactivity toward D1 sequences (amino acids 37–51 and 112–128,
respectively; data not shown). Alanine analogs of the 39 pentadeca-
peptides that corresponded to the Ab-binding sequences were then
synthesized using the SPOT method to identify the HER3 residues
that are critically involved in Ab binding (SCRs; see Figure 2, B and C ,
for an example). In summary, the alanine scanning experiments indi-
cated that the key bindingmotif forH4B-121 onD3 is 352DPWHKI358
and that Asp352, Trp354,His355, and Lys356 are themain SCRs.Moreover,
the observation that Trp354, His355, and Lys356 in 352DPWHKI358 are
phylogenetically conserved in mouse and monkey HER3 (Figure 3B)
explains why H4B-121 bound to both human and mouse HER3 in
ELISAs and suggests that H4B-121 might cross-react also with rhesus
monkey HER3 (Macaca mulatta). Conversely, the lack of sequence
conservation with human EGFR, HER2, and HER4 explains why
H4B-121 did not recognize other HER family receptors in flow cy-
tometry assays. Themotif 469RPRR-VA476 inD3was found to be critical
for binding of H4B-25 Ab and residues Arg471, Arg472, and Val475 were
the main SCRs (Figure 3A). Two SCRs (Arg471 and Arg472) and also
Asp473 are not conserved in mouse HER3 or in human EGFR, HER2,
and HER4 (Figure 3B), consistent with the absence of cross-reaction
for this Ab in ELISA and flow cytometric assays. However, as the
469RPRR-VA476 binding motif is conserved in monkey HER3, the
H4B-25 Ab might recognize monkey HER3. The 502RNY-R506
sequence in D4 was identified as the binding motif for H3A-122
and residues Tyr504 and Arg506 as the main SCRs (Figure 3A ). This
motif is conserved in the human and monkey HER3 sequences
(Figure 3B) but not in those of other HER family members (particu-
larly the SCR Tyr504), thus explaining the absence of cross-reaction
with other human HER family members (Figure 1, A and B). Alanine
scanning of pentadecapeptides in D1 identified 112L-LT-LTEILS122 as
the binding motif for 16D3-C1 and Leu120, Glu122, Ile123, and Leu124
as the main SCRs (Figure 3A). The amino acid difference at positions
114 and 125 might explain why 16D3-C1 did not bind to mouse
HER3. The Ab 9F7-F11 recognized the motif 44LEIVL48 in D1 and
residues Leu44, Ile46, and Leu48 were identified as SCRs (Figure 3A).
The 112L-LT-LTEILS122 (16D3-C1) and 44LEIVL48 (9F7-F11)
sequences are not conserved in other HER family receptors (Figure 3B),
explaining why these Abs did not cross-react with EGFR, HER2, or
EGFR/HER4. In contrast, the complete sequence homology with
monkey HER3 suggests that these Abs might cross-react with monkey
HER3 (Figure 3B ). We then positioned the SCRs of each binding
motif on the crystallographic structure of unliganded HER3 (pdb
1M6B; Figure 3C ). The H4B-121 binding motif 352DPWHKI358
protruded at the junction between D2 and D3, whereas 469RPRR-
VA476 (H4B-25) was close to the C terminus of D3 and 502RNY-R506
(H3A-122) was at the N terminus of D4. These two binding motifs
are opposite to the H4B-121 epitope. The H4B-25 binding motif,
which is involved in an α-helix structure, was within a “hot-spot” region
and overlapped with the HER3 epitope recognized by the “two-in-one”
EGFR/HER3 Ab MEHD7945A [27]. Moreover, it included amino
acid positions that align with residues that are critically involved in
the binding of MEHD7945A [27], matuzumab [31], nimotuzumab
[34], and cetuximab [35] to EGFR. The 9F7-F11 epitope 44LEIVL48
was located in one of the prominent β-strands at the beginning of
D1, facing the H4B-121 epitope at a distance of 60 Å across D2.
The 16D3-C1 binding motif 112L-LT-LTEILS122 was deeply located
inside the β-strand structure of D1.
Figure 2. The 352DPWHKI358 motif recognized by the Ab H4B-121
is located in D3 of HER3. (A) Scan analysis of the 213 overlapping
pentadecapeptides that covered the entire extracellular domain of
HER3 (amino acids 1–645) and were frame-shifted by one or three
residues (generated by the SPOT method). Binding of H4B-121
was observed only in the region between amino acids 340 and
360. No binding was observed with the secondary Ab alone. The
Spot intensity was measured using ImageJ. (B) Alanine scanning
(Alascan) of the pentadecapeptides 342LDFLITGLNGDPWHK356,
343DFLITGLNGDPWHKI357, and 344FLITGLNGDPWHKIP358 that cover
the region between amino acids 342 and 358 of HER3. (C) Quan-
titative analysis of H4B-121 binding to the membrane pentadeca-
peptides in B using ImageJ. Each bar represents the reactivity of
H4B-121 towardapentadecapeptide sequence inwhich the indicated
amino acid was substituted by alanine. The mean spot reactivity
for each residue was calculated from the results obtained in the
three pentadecapeptides.
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Figure 3. The Abs H4B-25 and H3A-122 recognize motifs located in D3 and D4, respectively, whereas the Abs 16D3-C1 and 9F7-F11 bind
to motifs within D1 of HER3. (A) Quantitative analysis of the reactivity of H4B-25, H3A-122, 16D3-C1, and 9F7-F11 toward pentadeca-
peptides generated by SPOT synthesis on cellulose membranes using ImageJ. (B) Amino acid alignment of the identified Ab-binding
motifs in human, monkey, and mouse HER3 and in human EGFR, HER2, and HER4. (C) The Ab-binding motifs were localized on the
crystal structure of unliganded HER3 (pdb 1M6B).
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The D1-Specific Abs 16D3-C1 and 9F7-F11 and the
D3-specific Ab H4B-121 Reduce Tumor Growth in
Mice Xenografted with Tumor Cells with
Different Biologic Profiles
To assess the anti-tumor activity of selected anti-HER3Abs in vivo, we
first xenografted subcutaneously nude mice with HER2 non-amplified
BxPC3 pancreatic cancer cells that express HER3 at low level (between
10,000 and 20,000 receptors/cell). When tumors reached a volume of
120 mm3, mice (n = 8/each condition) were treated with 15 mg/kg
anti-HER3 Ab 16D3-C1, 9F7-F11, or H4B-121, as single agents,
every 2 days for 6 weeks. At day 56 post-xenograft (corresponding to
day 26 of the Ab treatment), mean tumor volume was significantly
smaller (68 ± 4% reduction; P < .001) in Ab-treated mice than in mice
treated with vehicle (controls; Figure 4A, left panel). At the end of the
experiment (160 days), Kaplan-Meier analysis revealed that the 50%
median survival time was significantly delayed by 18 days in mice
treated with the anti-HER3 Abs 9F7-F11 and H4B-121 (Figure 4A,
right panel) and by 24 days (and one mice was completely cured) in
mice treated with 16D3-C1 in comparison to controls (P < .001).
Analysis of tumor samples at day 24 of treatment showed that HER3
phosphorylation at Tyr1289 was inhibited and HER3 was down-
regulated in Ab-treated mice in comparison to vehicle-treated mice
(Figure 4B ).
We next used these Abs to treat mice that had been xenografted
with NRG-addicted epidermoid A431 tumor cells [17] or triple-
negative breast cancer MDA-MB-468 cells. HER2 non-amplified
(HERlow) epidermoid A431 cells secrete the HER3 ligand NRG
[17] and express around 10,000 HER3 receptors per cell, whereas
MDA-MB-468 cells also express HER3 at low level (around 6000 to
8000 receptors per cell) and harbor mutant PTEN. As observed in
mice xenografted with BxPC3 cancer cells, mean tumor volume was
significantly lower in Ab-treated mice xenografted with A431 cells
(53 ± 6% reduction; n = 8 animals/condition) at day 31 post-xenograft
(20 days after the beginning of the treatment; Figure 4C , left panel; P <
.001) or with MDA-MB-468 cells (35% and 40% volume reduction
at day 105 post-xenograft following treatment with 9F7-F11 and
H4B-121, respectively; Figure 4D, left panel; P < .05) than in controls
(vehicle). Treatment with the 16D3-C1 and 9F7-F11 Abs significantly
delayed the 50% median survival time by 21 days in mice xenografted
with A431 cells (one mouse cured for both Ab groups at the end of
the experiment, i.e., 140 days; P < .001; Figure 4C , right panel) and
by 20 days in animals xenografted with MDA-MB-468 cells (one
mouse was stabilized for both Ab groups at the end of the experiment,
i.e., 190 days; P < .05; Figure 4D, right panel). Treatment with the Ab
H4B-121 delayed the median survival time by 14 days in animals xeno-
grafted with A431 cells (Figure 4C , right panel; P < .01) and by 61 days
in mice xenografted with MDA-MB-468 cells (three mice were stabi-
lized at the end of the experiment, i.e., 190 days; P < .01; Figure 4D,
right panel). Taken together, these results demonstrate that anti–HER3
D1 and D3 Abs delay tumor growth in mice xenografted with different
cancer cell lines, irrespectively of their biologic profile (i.e., NRG addic-
tion and HER2 status).
Combined Treatment with the Anti-HER3 Ab 16D3-C1 and
Trastuzumab Improves Inhibition of HER2low Tumor Growth
in Nude Mice
We previously demonstrated that the combination of anti-HER2
trastuzumab with anti-EGFR therapy has a synergistic anti-cancer effect
in mice xenografted with HER2low pancreatic carcinoma cells [36]. To
assess the effect on HER2low tumor xenografts of combined treatment
with trastuzumab and the anti-HER3 Ab 16D3-C1, we xenografted
mice (n = 8/each condition) with HER2low epidermoid A431 or lung
A549 cancer cells. Both cell lines secrete NRG [17,37] and show no
[38] or moderate [39] response to trastuzumab therapy, respectively.
To highlight a potential synergistic effect, sub-efficient doses of
16D3-C1 and trastuzumab (10 mg/kg every 2 days for 4 weeks) were
administered. Tumor growth was significantly reduced (60% in A431
cell xenografts and 75% in A549 cell xenografts) in mice treated with
both Abs (P < .001) at day 35 post-xenograft in comparison to mice
treated with 16D3-C1 alone (25% reduction in A431 and 50% reduc-
tion in A549 xenografts) or with trastuzumab alone or vehicle (no
reduction; Figure 5). These results demonstrate that the combination
of anHER3-specific Ab and trastuzumabmight be effective inHER2low
carcinomas that secrete NRG.
Anti-HER3 Abs Induce Cell Cycle Arrest in G1 Phase,
Leading to Proliferation Inhibition and Apoptosis of
Pancreatic BxPC3 Cancer Cells
As our anti–HER3 D1 and D3 Abs efficiently inhibited tumor
growth in vivo alone or in combination with trastuzumab, we then
investigated in vitro their effects on cell cycle, proliferation, and
apoptosis. Exposure of NRG-stimulated BxPC3 pancreatic cancer
cells to the Abs 9F7-F11 and 16D3-C1 for 24 hours induced cell
cycle arrest in G1 phase (particularly in cells incubated with 9F7-
F11), leading to a lower number of cells in S and G2/M phases in
comparison to untreated cells or cells incubated with the irrelevant
Px Ab (controls; Figure 6A). An anti-proliferative effect of the three
anti-HER3 Abs was observed at 120-hour post-incubation (Fig-
ure 6B). Moreover, early and late apoptosis of ligand-stimulated
BxPC3 cells was also observed upon exposure to HER3-specific Abs
9F7-F11 and 16D3-C1 (Figure 6C ). These results indicate that anti-
HER3 Abs induce cell cycle arrest, leading to subsequent proliferation
inhibition and apoptosis, in agreement with their inhibition of tumor
growth in vivo.
The Abs 16D3-C1, 9F7-F11, and H4B-121 Block HER2/
HER3 Dimerization
Members of the HER family modulate their downstream signal-
ing and oncogenic effects through receptor homodimerization and
heterodimerization. Using a recently described Ab-based TR-FRET
assay [32], we assessed whether our HER3-specific Abs could block
HER2/HER3 heterodimerization in NIH/3T3 cells that express
both HER2 and HER3. These cells were chosen because 1) they ex-
press more HER3 receptors (946,000/cell) than HER2 receptors
(126,000/cell), thus allowing a better fluorescence signal to follow
heterodimer formation, and 2) they were sensitive to the inhibitory
effects of HER3 Abs in a cell proliferation assay (24 ± 6% inhibition
with 16D3-C1, 32 ± 9% with 9F7-F11, and 22 ± 1% with H4B-
121, respectively). In the absence of exogenous NRG stimulation, a
significant dose-dependent disruption of HER2/HER3 heterodimers
was observed when cells were incubated with the Abs 16D3-C1 and
9F7-F11 (around 30%) or H4B-121 (38%) in comparison to un-
treated cells (Figure 7; P < .001). Trastuzumab treatment also
blocked HER2/HER3 heterodimerization in a dose-dependent way
in these cells. Conversely, incubation with exogenous NRG increased
HER2/HER3 formation (up to 60%), as expected [5]. Pre-incubation
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Figure 4. The anti–HER3 D1 Abs 9F7-F11 (▪) and 16D3-C1 (▵) and the anti-HER3 D3 Ab H4B-121 (○) inhibit tumor growth (left panel)
and increase survival time (right panel) compared to vehicle (NaCl; ♦) in mice xenografted with HER2 non-amplified pancreatic car-
cinoma BxPC3 cells (wild-type PIK3CA and p53) (A), NRG-addicted, HER2 non-amplified epidermoid carcinoma A431 cells (wild-type
PIK3CA and mutant p53) (C), or triple-negative, EGFR-amplified breast carcinoma MDA-MB-468 cells (wild-type PIK3CA and mutant
p53) (D). BxPC3 tumor lysates from vehicle- or Ab-treated mice were prepared 24 days after the beginning of the treatment (tumor
sizes are indicated) and HER3 phosphorylation at Tyr1289 was assessed by Western blot analysis (B). Tumor growth data are pres-
ented as the mean tumor volume ± SEM for each group of nude mice (n = 8 per condition, but for the MDA-MB-468 xenograft
model, n= 7). Kaplan-Meier survival curves were calculated when tumors reached a volume of 2000 mm3 and mice were sacrificed.
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with the control Ab Px did not influence HER2/HER3 dimer forma-
tion (Figure 7). Finally, HER3-specific Abs did not modify HER2
and HER3 expression (data not shown). Taken together, these results
indicate that anti-HER3 Abs act by disrupting HER2/HER3 hetero-
dimerization at the cell membrane.
TheAbs 16D3-C1, 9F7-F11, andH4B-121 InhibitHER2/HER3
Phosphorylation, Leading to Blockade of AKT-Induced
Phosphorylation of Apoptosis- and Proliferation-Related
Signaling Proteins
We next evaluated the effect on downstream cell signaling of the
NRG antagonist Abs 16D3-C1 and H4B-121 and of the NRG-
independent Ab 9F7-F11. To this end, we used the pancreatic BxPC3
cancer cell line in which NRG potently activates the HER2/HER3
pathway. The D1-specific Ab 9F7-F11 blocked ligand-induced phos-
phorylation at various Tyr residues of HER2 and HER3 (Figure 8A).
Particularly, 9F7-F11 inhibited HER3 phosphorylation at Tyr1289,
which showed no basal activation, and at Tyr1262, which demonstrated
high basal activation. Tyr1289 HER3 interference was also observed, but
at a lower level, with the NRG antagonist Abs 16D3-C1 andH4B-121.
Moreover, short incubation (15 minutes) with 16D3-C1, 9F7-F11, or
H4B-121 also inhibited AKT phosphorylation on Ser473 and Thr308 as
well as phosphorylation of AKT downstream targets, such as the S6
ribosomal protein (which regulates protein translation), GSK3 (which
regulates cell cycle and cell proliferation), FoxO1 and XIAP (which
modulate apoptosis and cell survival), and MDM2 (which regulates
p53 degradation; Figure 8A). We then investigated whether the anti-
HER3 Abs could downregulate HER3 expression in BxPC3 cells.
Short-time incubation (15 minutes) at 37°C did not induce receptor
down-regulation. In contrast, 1- to 2-hour exposure at 37°C strongly
reduced, in a time-dependent manner, HER3 expression, as indicated
by Western blot quantification. Ab-induced HER3 down-regulation
was abrogated when cells were incubated at 4°C (Figure 8B ), thus
suggesting that HER3-specific Abs promote HER3 internalization
and degradation.
Discussion
Therapeutic inhibitors of tyrosine kinase receptors that directly rely
on the PI3K/AKT pathway, such as HER3, should affect proteins
that regulate apoptosis and cell survival and also factors involved in
compensatory signaling and drug resistance. Here, we provide evi-
dence that anti–HER3 D1 and D3 Abs inhibit in vivo tumor growth
by reducing HER2/HER3 dimerization and phosphorylation and, as
a consequence, phosphorylation of AKT and AKT downstream tar-
gets, such as XIAP, MDM2, and FoxO1. The anti–HER3 D1 and
D3 Abs showed comparable high anti-tumor activity independently
of the triple-negative status (MDA-MB-468 breast cancer cells) and
NRG addiction (epidermoid A431 cells and A549 lung carcinoma
cells) of the xenografted cancer cell lines and also in BxPC3 xeno-
grafts. BxPC3 cells were derived from a pancreatic adenocarcinoma,
a type of cancer for which very few therapeutic options (and with
very modest effects) are available at the moment.
The increased anti-cancer activity of the trastuzumab/anti-HER3
Ab combination in tumor xenografts of HER2low cancer cells (in
which trastuzumab alone shows no or low efficacy) could open
new indications for anti-HER3 therapies, in addition to HER2high
[27,29,40] and EGFRhigh [25,27] tumors. The main rationale for
these combinations is that HER3 overexpression is triggered by
monotreatment with EGFR- and HER2-specific Abs or small kinase
inhibitors, thus allowing compensatory oncogenic signaling and cell
resistance [20,25] that could be overcome with a dual therapy, as
demonstrated for the EGFR-targeted therapy/anti-HER3 Ab combi-
nation in a mouse model of lung cancer [25]. Our data indicate that the
anti-HER3 Ab/trastuzumab combination might represent an option
for bypassing trastuzumab-induced resistance in HER2-amplified can-
cer but also for targeting HER2low cancer. Moreover, the synergistic
effect of two HER3-specific Abs (e.g., NRG antagonism for Ab
16D3-C1 or H4B-121 and NRG-independent binding for Ab 9F7-
F11), or a combination of anti-HER3 Abs plus chemotherapy [27]
or radiotherapy [41], could be also envisaged to more efficiently block
NRG-addicted as well as NRG-independent HER3-positive tumors.
We obtained mouse and human D1-, D3- and D4-specific Abs
that can interfere or not with ligand binding. The alanine scanning
analysis shows that, although charged and aromatic residues are both
critical for HER3 binding by our Abs (e.g., Asp352, Trp354, His355, and
Lys356 for H4B-121), non-polar aliphatic residues are also involved
in HER3 binding, particularly of 9F7-F11 and 16D3-C1 (e.g.,
Leu120, Ile123, and Leu124). As the motifs recognized by the 9F7-F11
and H4B-121 Abs overshadow the hidden D2 domain, the NRG-
independent 9F7-F11 Ab might limit the NRG-induced intra-
molecular and intermolecular flexibility of HER3, as was suggested
for zalutumumab (specific for EGFR D3), whereas the NRG antago-
nist H4B-121 and 16D3-C1 Abs might occlude the ligand-binding
Figure 5. Dual treatment with the anti–HER3 D1 Ab 16D3-C1 and
trastuzumab (.) improves tumor growth inhibition in nude mice
xenografted with HER2low A431 epidermoid (A) or A549 lung
(B) carcinoma cells in comparison to mice treated with vehicle
(NaCl; ♦), 16D3-C1 (▵) or trastuzumab (○) alone. Tumor growth
data are presented as the mean tumor volume ± SEM for each
group of eight nude mice.
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domain, as was previously shown for cetuximab [35]. D1- and D3-
specific Abs probably inhibit HER2/HER3 cellular heterodimerization
by locking HER3 in a conformation that impairs the formation
of HER3-containing dimers. Heterodimerization was not inhibited
by the Abs H4B-25 and H3A-122 directed against the “hot-spot”
D3/D4 junction, suggesting that this HER3 region is not directly
involved, when D1 and D2 move further away from D3 and D4,
after NRG activation, to open the receptor in an active conformation
for dimerization. However, HER3 epitope targeted by D3-specific Ab
H4B-25 perfectly matched with residues identified by the A30 aptamer
[42], thus suggesting that this Ab could interfere with the side-by-side
rearrangement of HER2/HER3 heterodimers leading to the formation
of dimers, as proposed by Zhang et al. [42]. D4-specific Ab H3A-122
will rather act by sterically locked D2/D4 interdomain tether, thus
hindering NRG binding [43].
An important feature of the anti–HER3 D1- and D3-specific Abs is
their ability to inhibit NRG-induced phosphorylation of XIAP, FoxO1,
GSK3, and MDM2. HER3 C-terminal tail has six YXXM motifs that
are phosphorylated after NRG stimulation and that directly engage the
N-SH2 domain of p85 and thus activate the p110 catalytic subunit
Figure 6. The anti-HER3 Abs block NRG-stimulated BxPC3 pancreatic cancer cells in the G1 phase of the cell cycle (A), inhibit their
proliferation (B), and promote cell apoptosis (C). Cell cycle progression was analyzed using propidium iodide staining; cell proliferation
was quantified on the basis of the cell incorporation of Alexa Fluor 488–conjugated 5-ethynyl-2′-deoxyuridine, and apoptosis was dem-
onstrated by staining with Annexin V and 7-aminoactinomycin D.
Figure 7. The anti–HER3 D1 Abs 16D3-C1 and 9F7-F11 and the
anti-HER3 D3 Ab H4B-121, but not the Abs 12H8-B11, H4B-25,
and H3A-122, block HER2/HER3 heterodimerization in NIH/3T3 fibro-
blasts that express HER2 and HER3. The concentration of HER3 Abs
or NRG is indicated. The blockade of HER2/HER3 heterodimerization
was quantified by using Ab-based TR-FRET assays.
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Figure 8. The anti–HER3 D1 Abs 16D3-C1 and 9F7-F11 and the anti-HER3 D3 Ab H4B-121 inhibit NRG-induced phosphorylation of
HER3 as well as of AKT, leading to reduced phosphorylation of the downstream targets MDM2, XIAP, FoxO1, and GSK-3 (A) and to
HER3 down-regulation (B). BxPC3 carcinoma cells were incubated with anti-HER3 Abs or the control Ab Px for various times and
then stimulated with NRG for 10 minutes. Phosphorylation was analyzed after 15-minute Ab incubation at 37°C by Western blot analysis
using the appropriate Abs. HER3 down-regulation was determined after Ab incubation at 37°C or 4°C for 15 minutes, 1 hour, and 2 hours.
M, medium.
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of PI3K. Recruitment and activation of PI3K leads to phosphoryla-
tion and activation of membrane-bound AKT by phosphoinositide-
dependent kinase-1 (PDK1) and target of rapamycin (TOR) complex 2.
Incubation with the Abs 16D3-C1 and 9F7-F11 (anti–HER3D1) and
the Ab H4B-121 (anti–HER3 D3) blocked AKT phosphorylation at
Thr308 [(induced by PDK1) and at Ser473 (mediated by mammalian
target of rapamycin (mTOR)], demonstrating that both PDK1 or
mTOR signaling cascades are affected. AKT is a major signaling
“hub” that phosphorylates a plethora of cell substrates and, as a con-
sequence, can also influence tumor growth and drug resistance [5].
For instance, XIAP belongs to a family of proteins that cause innate
and drug-induced resistance to apoptosis in EGFR- or HER2-positive
cancer cells [44]. By inhibiting XIAP phosphorylation, our anti-HER3
Abs could favor its ubiquitination/degradation and consequently re-
establish functional apoptosis in native and drug-resistant cancer cells.
Nuclear FoxO1 can initiate apoptosis by inducing FasL transcription
and by activating the pro-apoptotic Bcl2 family member Bim. AKT-
induced phosphorylation of FoxO1 results in the export of phosphory-
lated FoxO1 from the nucleus to the cytoplasm and in its ubiquitination/
degradation, thereby inhibiting FoxO1-dependent transcription. Over-
expression of FoxO factors inhibits tumor growth in vitro and in vivo in
breast cancers and FoxO cytoplasmic localization correlated with poorer
survival in breast cancer patients [45]. By inhibiting FoxO1 phosphory-
lation, anti-HER3 Abs retain active FoxO1 in the nucleus and directly
promote apoptosis of tumor cells by activating the FasL/Bcl2 pathways,
as was previously demonstrated for trastuzumab [46]. However, FoxO
factors also favor the transcriptional and posttranslational up-regulation
of HER3 to compensate for the AKT inhibition induced by treatment
with PI3K [21] and EGFR/HER2 [20,47] inhibitors in breast cancer.
Therefore, dual treatment with anti-HER3 Abs (to target its drug-
induced up-regulation) and kinase inhibitors should have higher anti-
tumor activity.Moreover, FoxO knockout suppresses the induction and
phosphorylation of HER3 and also of insulin receptor IGF1R [47] and
the fibroblast growth factor (FGF) receptor [21], highlighting the lay-
ered interconnected tyrosine kinase receptor networks that could be
concomitantly modulated by HER3-specific Abs. Finally, MDM2,
an E3 ubiquitin ligase that regulates p53 by promoting its ubiquitina-
tion/degradation, also favors FoxO1 ubiquitination/degradation [48].
FoxO factors and p53 perform similar functions to enable DNA repair,
maintain genomic stability, and coordinate cell cycle regulation and
apoptosis through multiple tumor-suppressor mechanisms. XIAP pos-
sesses an E3 ubiquitin ligase activity that inhibits caspases 3, 7, and 9
through ubiquitination/degradation [49]. Thus anti-HER3 Abs can in-
directly restore the functionality of apoptotic- and proliferative-related
proteins by regulating AKT-induced ubiquitination of key components
of signaling cascades, such as XIAP, MDM2/p53, and FoxO factors. In
addition, p53 regulates acquired resistance and sensitivity to receptor
tyrosine kinase (RTK) inhibitors [50], and anti-EGFR/HER3 Ab
MEHD7945A has been recently demonstrated to increase p53 phos-
phorylation [41], suggesting that bypassing resistance to RTK inhibi-
tors by modulating the p53 pathway through HER3 targeting could be
an interesting way of investigation.
The binding of 9F7-F11 Ab to HER3 is NRG-independent, but
this Ab inhibited ligand-induced phosphorylation of HER3 and Akt,
thus confirming that it rather acts by impairing dimer formation.
While a 15-minute incubation with anti-HER3 Abs was sufficient to
block NRG-induced phosphorylation of HER3 and AKT, Ab-induced
HER3 down-regulation inNRG-stimulated BxPC3 cells occurred later,
at least after 1 hour of incubation, and persisted throughout the exper-
iment time course. TheHER3-specific Absmight thus regulate receptor
quality control [4] by accelerating HER3 endocytosis, sorting, and deg-
radation, as previously proposed by others [24–26,28]. Upon ligand
binding, HER3 turnover is rapid, probably chronologically regulated
by its HER heterodimerization partner (mainly HER2) and dependent
on ubiquitination/deubiquitination triggered by the Nrdp1/USP8
complex [51] for degradation through the proteasomal pathway [52].
As the membrane is a “meeting point” for extracellular therapeutic
Abs and intracellular pathways, we postulate that anti-HER3 Abs act
by affecting HER3 membrane compartmentalization and, conse-
quently, impairing HER heterodimerization and downstream
AKT-triggered MDM2/FoxO1/XIAP signaling. Collectively, these
results demonstrate that anti–HER3 D1 and D3 Abs are efficient
targeted therapies to overcome drug resistance or as novel therapeutic
options for pancreatic cancer and triple-negative breast cancer.
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Supplementary Materials
Cell Lines
The human pancreatic (BxPC-3), breast (MDA-MB-468), epider-
moid (A431), and lung (A549) cancer cell lines were from ATCC.
Themouse embryonic fibroblast NIH/3T3 cell line was kindly provided
by S. Schmidt (CNRS-UMR 5237, Montpellier, France). EGFR-,
HER2-, HER3-, HER2/HER3-, and EGFR/HER4-transfected
NIH/3T3 cell lines were obtained as previously described [32].
BxPC-3 cells were cultured in RPMI 1640; NIH/3T3, A431, A549,
and MDA-MB-468 cells were cultured in Dulbecco’s modified Eagle’s
medium. The complete culture media were supplemented as recom-
mended by ATCC, usually with 10% FCS. All culture media and sup-
plements were purchased from Life Technologies, Inc (Gibco BRL,
Gaithersburg, MD). Cells were grown at 37°C in a humidified atmo-
sphere of 5% CO2 and medium was replaced twice a week.
Ab Generation
As previously described [33], the human scFv phage library (MG-
Umab) was generated by combining donor Ab sequences obtained
from a wide naive Ab population and a naturally oriented Ab popu-
lation against several pathologies (100 donors). It was then further
customized by random mutagenesis of the entire variable domain,
thus mimicking the in vivo process of Ab diversity, and finally cloned
in fusion with the β-lactamase gene to eliminate premature stop codon
sequences. To select HER3-binding clones, the library MG-Umab
(size, 3.4 × 109; 94% of clones coding full-length Abs) was subjected
to four rounds of selection in eight-well MaxiSorp immunoplates
that had been previously coated with 1 μg of HER3-Fc. For the last
three rounds of selection, a depletion step with human IgG1 was intro-
duced before incubation to avoid the selection of Fc binders. After
selection, 96 individual phage-infected colonies from the third round
and 48 from the fourth round of selection were randomly picked and
used to produce phage-scFv particles in 96-well plates. HER3-specific
phage-scFv were screened byELISA using 500 ng/mlHER3-Fc as target
and HRP-labeled anti-M13 secondary Ab (1/10,000 dilution; GE
Healthcare, Chalfont, United Kingdom) as detection Ab. Each phage-
scFv was tested simultaneously for binding to HER3-Fc and to BSA
(control) as control. Nine clones showing the higher positive signal
(HER3 signal up to three times stronger than the BSA signal) were
sequenced and expressed as fully human IgG1 for further characterization.
To obtain HER3-specific mouse monoclonal Abs, BALB/c mice
were injected subcutaneously with 10 μg of soluble HER3-Fc or intra-
peritoneally with 2 × 106 HER2/HER3-transfected NIH/3T3 cells
(previously stimulated with 100 ng/ml NRG to favor HER2/HER3
heterodimer formation) at days 0, 14, and 28. To monitor the Ab re-
sponse, Ab titers weremeasured by ELISA or flow cytometry. After a last
boost with the antigens 3 days before fusion, spleen cells from one
HER3-Fc–immunized and one HER2/HER3 NIH/3T3-immunized
mouse were fused according to the protocol already described using
the PX63Ag8.653 myeloma cell line. Fused cells were cultured in
96-well plates (100,000 cells/well) with hypoxanthine-aminopterin-
thymidine (HAT) medium for hybridoma selection. Hybridoma
supernatant screening was performed by ELISA using 250 ng/ml
HER3-Fc or Fc alone (control) as antigens at day 12 post-fusion.
Ten HER3-specific hybridomas were cryopreserved and cloned before
experiments. The hybridoma cell line that produces the anti-HER3 Ab
16D3-C1 was deposited in the Collection Nationale de Cultures de
Microorganismes (Institut Pasteur, Paris, France) under the reference
CNCM I-4486.
HER3 Binding Studies
The binding specificity of selected Abs to soluble HER3 was
assessed by ELISA. ELISA 96-well microplates (Nunc, Paisley, United
Kingdom) were coated with 250 ng/ml human or mouse HER3-Fc
antigen in PBS buffer at 4°C overnight. After four washes in PBS/
0.1% Tween 20 (PBS-T) and saturation with 1% BSA in PBS-T at
37°C for 1 hour, 100 μl of 1 μg/ml dilution of anti-HER3 Abs in
PBS-T were added to each well. After incubation for 2 hours and
four washes in PBS-T, bound Abs were detected by incubation with
peroxidase-conjugated goat F(ab)′2 polyclonal Abs (1:10,000 dilution)
against human or mouse F(ab)′2 fragments (Jackson ImmunoResearch)
for 1 hour, followed by addition of the peroxidase substrate. Absor-
bance was measured at 450 nm. Three replicates of each dilution
were performed and each experiment was done three times; shown data
correspond to the mean value of absorbance ± SD.
The kinetic parameters of the binding of selected Abs to HER3
were determined at 25°C by surface plasmon resonance analysis using
a BIACORE 3000 instrument (BIACORE AB, Uppsala, Sweden).
HER3-specific Abs were immobilized on the CM5 sensor chip surface
using a rabbit anti-mouse or anti-human polyclonal Ab (Sigma-
Aldrich) according to the manufacturer’s instructions. Recombinant
HER3 in HBS-EP buffer [10 mM Hepes (pH 7.4), 3 mM EDTA,
150 mM NaCl, and 0.005% non-ionic surfactant P20 (GE Health-
care)] was injected at concentrations between 3.12 and 200 nM over
the flow cell, and the dissociation phase was followed by a regenera-
tion step with 10 mMHCl solution. The flow rate was 50 μl/min. All
sensorgrams were corrected by subtracting the control flow cell signal.
Data were globally fitted to a Langmuir 1:1 model using the BIA-
evaluation version 4.1.1 software.
The binding specificity of selected Abs to membrane HER3 was
assessed by flow cytometry. One million HER3- and HER2/HER3-
transfected NIH/3T3 cells or control cells (parental NIH/3T3 cells,
EGFR-, HER2-, and EGFR/HER4-transfected cells) [32] were incu-
bated with 20 μg/ml anti-HER3 Abs in PBS buffer without Ca++ and
Mg++ and supplemented with 1% BSA (PBS–1% BSA) at 4°C for
1.5 hours. After three washes in PBS–1% BSA, cells were incubated
with fluorescein-conjugated goat anti-human (1:60) or anti-mouse
(1:100) Fc Abs (Sigma-Aldrich) in the dark at 4°C for 1 hour. Cells
were then washed three times and suspended in PBS for analysis using
an FC500 flow cytometer (Beckman Coulter).
Western Blot Analysis
BxPC3 tumor cells were plated at 500,000 cells/well in six-well
culture plates and cultured at 37°C for 24 hours. After serum starva-
tion in RPMI complete medium with 1% FCS for 16 hours, cells
were washed and pre-incubated in 50 μg/ml anti-HER3 Abs or Px
Ab (negative control) at different temperatures and for various times,
before washing and stimulation with 100 ng/ml NRG for 10 minutes.
Cells were then washed, scraped, and lysed with buffer containing
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 1 mM
EDTA, 1% Triton, 10% glycerol, 0.1 mM phenylmethylsulfonyl
fluoride, 100 mM sodium fluoride, 1 mM sodium orthovanadate
(Sigma-Aldrich), and one tablet of complete protease inhibitor mixture
(Roche Diagnostics, Indianapolis, IN). After 30 minutes, the insoluble
fraction was eliminated by centrifugation and protein concentrations in
cell lysates were determined by the Bradford assay. Protein lysates were
directly mixed with Laemmli buffer and heated at 95°C for 5 minutes.
After sodium dodecyl sulfate–polyacrylamide gel electrophoresis under
reducing conditions, proteins were transferred to polyvinylidene di-
fluoride membranes (Millipore), which were then saturated in TNT
buffer [25 mM Tris (pH 7.4), 150 mM NaCl, 0.1% Tween] contain-
ing 5%non-fat drymilk at 25°C for 1 hour.Membranes were incubated
with primary Abs against kinase receptors or signaling kinases and their
phosphorylated forms in TNT/5% BSA buffer at 4°C for 18 hours.
After five washes in TNT buffer, peroxidase-conjugated rabbit, goat,
or mouse polyclonal Abs (Sigma-Aldrich) were added, as appropriate,
inTNTbuffer containing 5%non-fat drymilk at 25°C for 1 hour. After
five washes in TNT buffer, blots were visualized using a chemilumines-
cent substrate (Western Lightning Plus-ECL; PerkinElmer).
HTRF Analysis of HER2/HER3 Heterodimerization
HER2/HER3 heterodimers were quantified using Ab-based TR-
FRET assay, as previously described [32]. The assay was performed
on adherent cells using the anti-HER2 Ab FRP5 and the anti-HER3
Ab 15D4-F2 that were labeled with Lumi4-terbium cryptate or D2
acceptor dye, respectively (Cisbio Bioassays, Bagnol-sur-Cèze, France).
These Abs recognize epitopes that are different from those of the Abs
under study, and thus, no interference was observed in the TR-FRET
assay (data not shown). HER2/HER3-transfected NIH/3T3 cells were
plated at 3 × 105 per well in 96-well sterile black microplates in
Dulbecco’s modified Eagle’s medium (without phenol red) supplemen-
ted with 10% FCS. After 24 hours, cells were incubated with the anti-
HER3 Abs or NRG at concentrations ranging from 0.625 nM to
625 nM at 37°C for 30 minutes. After washing in KREBS buffer, cells
were fixed in 10% formalin (Sigma-Aldrich) for 2 minutes and washed
once with KREBS. After incubation with 5 nM FRP5 and 15D4-F2 in
KREBS buffer at 37°C for 6 hours, cells were washed four times with
KREBS buffer. The fluorescence of Lumi4-terbium and D2 were
measured, respectively, at 620 and 665 nm (60-μs delay and 400-μs
integration) upon 337-nm excitation on a Pherastar FS instrument
(BMG Labtech, Offenburg, Germany). The TR-FRET signal was
expressed as ΔF665(%) = ΔF665/F665Tb, with ΔF665 = F665c −
F665Tb, as previously explained [32], and then data were presented
considering the untreated sample as having 100% dimerization.
